DexCom stock rises 3.46% and snaps five-day losing streak

8 articles · Updated · MarketWatch · Apr 30

Shares closed at $59.55 on Thursday as the S&P 500 gained 1.02% to 7,209.01 and the Dow rose 1.62% to 49,652.14.
DexCom outperformed Abbott Laboratories, whose shares fell 0.59%, but lagged Insulet, which jumped 7.57% in the same session.
Trading volume reached 5.3 million shares, above its 50-day average of 4.1 million, though the stock remains 33.82% below its 52-week high of $89.98.

With its top rivals crippled by deadly recalls, is DexCom now the undisputed king of the glucose monitoring market?

DexCom's new OTC sensor is available without a prescription. Will this consumer-first approach revolutionize how we manage diabetes?

As major recalls reveal fatal flaws in diabetes tech, can patients still trust the devices they depend on to survive?